FLAER Based Assay According to Newer Guidelines Increases Sensitivity of PNH Clone Detection
- 12 Downloads
Flow cytometry has become ‘gold standard’ for detecting abnormal clones in paroxysmal nocturnal hemoglobinuria (PNH), aplastic anemia (AA) and myelodysplastic syndrome (MDS). This pilot study was conducted in 2015 with a primary aim to evaluate the utility of single tube fluorescent aerolysin (FLAER) based testing and its comparison with two tubes non-FLAER based testing (CD55, CD59, CD24 and CD66b) in detecting abnormal PNH clones in these newly diagnosed cases. The secondary aim was an attempt to distinguish PNH from AA/MDS cases associated with PNH clones based on clinical, laboratory features and clone size at diagnosis. In this study, the abnormal PNH clones were detected using a single tube FLAER based testing and two tubes non-FLAER based testing in all cases of PNH (n = 12), healthy subjects (n = 18) and AA/MDS with PNH clone (n = 9) and compared with clinical and laboratory features at diagnosis. The receiver operator curve (ROC) analysis defined the optimal cut-offs for FLAER in granulocytes (> 0.7%) and monocytes (> 0.9%). There was significant positive correlation between FLAER and non-FLAER based testing in these cells (r > 0.3 and p < 0.05). FLAER based testing helped us in picking up smaller clones which were missed by latter technique in four patients thereby increasing its sensitivity and also technically proved to be cost-effective (Rs. 1800 vs. Rs. 2100). Even in PNH patients, the clone size was slightly higher by using FLAER when compared to non-FLAER based antibodies panel. The clone size of monocytes was always higher than granulocytes in both PNH and AA/MDS groups. Bone marrow cellularity and mean size of granulocytes and monocytes clone at diagnosis showed a striking statistically significant ‘p’ value of < 0.0001 between these groups. In this pilot study, a single tube FLAER based PNH testing had improved clone detection in all cases of PNH, AA/MDS with PNH clones. The clone size was > 30% in majority of PNH cases whereas in AA/MDS, it was usually < 10% at diagnosis. Hence this newer technique not only increased the sensitivity of PNH clone detection but also proved to be cost-effective.
KeywordsFLAER Paroxysmal nocturnal hemoglobinuria Aplastic anemia Myelodysplastic syndrome
We thank “Indian Society of Hematology and Blood Transfusion” for funding Rs. 50,000/– Grant for this study.
Funding was provided by HERS and Indian Society of Hematology and Blood Transfusion (Grant No. IESC/T-161/02.05.2014).
Compliance with Ethical Standards
Conflict of interest
The author declares that they have no conflict of interest.
- 8.Brunning RD, Orazi A, Germing U, Beau MM, Porwit A, Baumann I et al (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al (eds) WHO classification of tumors of haematopoietic and lymphoid tissue, 4th edn. IARC Press, Lyon, pp 88–93Google Scholar
- 9.Borowitz MJ, Craig FE, DiGuiseppe JA, Illingworth AJ, Rosse W, Sutherland DR et al (2010) On behalf of the Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytom B Clin Cytom 78:211–230Google Scholar
- 15.Illingworth A, Marinov I, Sutherland DR, Wagner-Ballon O, DelVecchio L (2018) ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related Disorders Part 3: data analysis, reporting and case studies. Cytom Part B 94B:49–66CrossRefGoogle Scholar
- 16.Hernandez-Campo PM, Almeida J, Sanchez ML, Malvezzi M, Orfao A (2006) Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: a frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria. Cytometry 70:71–81CrossRefGoogle Scholar
- 21.Wang SA, Pozdnyakova O, Jorgensen JL, Medeiros LJ, Stachurski D, Anderson M et al (2009) Detection of paroxysmal nocturnal hemoglobinuria clones in patients with myelodysplastic syndromes and related bone marrow diseases, with emphasis on diagnostic pitfalls and caveats. Haematologica 94:29–37CrossRefGoogle Scholar